KODKodiak Sciences IncSigning up patients
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO
Diabetic Macular Edema (DME)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 910 (planned)
- Started
- Aug 3, 2026
- Main results expected
- Aug 31, 2028
- Fully finished
- Sep 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Best corrected visual acuity (BCVA)
Measured over: Week 52
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07734844 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC